When comparing the groups of patients, subjects affected by iNPH showed higher CSF orexin-A levels than those with mAD and bv-FTD; conversely, patients with msAD showed higher CSF orexin-A levels than those with mAD; and patients with both NFPA and bv-FTD presented higher CSF orexin-A levels than patients with mAD. This evidence concerns the gene HCRT and non-functioning pituitary adenoma.